Drug:
Reaction: MALIGNANT NEOPLASM PROGRESSION
20250101 - 20251231
No. 801 - 900
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 801 | 24959562 |
US |
65 | 1 |
Malignant neoplasm progression, Aggression, Hostility, |
||||
ENZALUTAMIDE, |
||||
| 802 | 24960574 |
GB |
57 | 2 |
Malignant neoplasm progression, Pancytopenia, Thrombocytopenia, Neutrophil count decreased, Alanine aminotransferase increased, Off label use, |
||||
CABOZANTINIB, CABOZANTINIB, AMLODIPINE, |
||||
| 803 | 24960899 |
TW |
72 | 1 |
Pneumonitis, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PACLITAXEL, PACLITAXEL, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CISPLATIN, CISPLATIN, CISPLATIN, |
||||
| 804 | 24961024 |
CA |
||
Malignant neoplasm progression, Cardiac dysfunction, |
||||
OSIMERTINIB, |
||||
| 805 | 24961106 |
TH |
1 | |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 806 | 24961448 |
CH |
||
Malignant neoplasm progression, |
||||
DURVALUMAB, CISPLATIN, GEMCITABINE HYDROCHLORIDE, |
||||
| 807 | 24961522 |
HU |
68 | 1 |
Prostate cancer metastatic, Malignant neoplasm progression, Osteonecrosis of jaw, |
||||
ZOLEDRONIC ACID, |
||||
| 808 | 24961798 |
GB |
||
Deep vein thrombosis, Malignant neoplasm progression, Renal impairment, Therapy partial responder, |
||||
CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 809 | 24961850 |
US |
74 | 2 |
Malignant neoplasm progression, |
||||
LENVATINIB, AMLODIPINE, FISH OIL, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, PEMBROLIZUMAB, NIFEDIPINE, CARVEDILOL, FUROSEMIDE, BISOPROLOL FUMARATE, |
||||
| 810 | 24962137 |
US |
28 | 2 |
Cardiac arrest, Oesophageal stenosis, Oesophagobronchial fistula, Oesophageal rupture, Dysphagia, Malignant neoplasm progression, Paronychia, Xeroderma, Dermatitis acneiform, Diarrhoea, |
||||
SELPERCATINIB, SELPERCATINIB, TRAMETINIB, TRAMETINIB, TRETINOIN, |
||||
| 811 | 24962593 |
DE |
1 | |
Malignant neoplasm progression, Palliative care, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, |
||||
| 812 | 24953050 |
GB |
1 | |
Malignant neoplasm progression, Off label use, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 813 | 24953363 |
FR |
54 | |
Drug resistance, Malignant transformation, Malignant neoplasm progression, Acquired gene mutation, |
||||
OSIMERTINIB, |
||||
| 814 | 24953415 |
BE |
65 | |
Off label use, Malignant neoplasm progression, |
||||
OSIMERTINIB, OSIMERTINIB, |
||||
| 815 | 24953449 |
US |
74 | 1 |
Malignant neoplasm progression, Adverse drug reaction, |
||||
NIVOLUMAB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, APIXABAN, SODIUM BICARBONATE, SODIUM BICARBONATE INJECTION,, |
||||
| 816 | 24953820 |
DE |
||
Death, Pancytopenia, Malignant neoplasm progression, |
||||
CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, PEMBROLIZUMAB, |
||||
| 817 | 24954462 |
DE |
34 | 2 |
Malignant neoplasm progression, |
||||
LETROZOLE, LETROZOLE TABLETS, ABEMACICLIB, GOSERELIN, |
||||
| 818 | 24954561 |
CA |
29 | 2 |
Malignant neoplasm progression, Ovarian cancer, Abdominal pain, Nausea, |
||||
LETROZOLE, LETROZOLE TABLETS, |
||||
| 819 | 24955808 |
86 | ||
General physical health deterioration, Myelofibrosis, Malignant neoplasm progression, Drug ineffective, |
||||
RUXOLITINIB, |
||||
| 820 | 24955811 |
73 | ||
Quality of life decreased, Myelofibrosis, Malignant neoplasm progression, Myelosuppression, Platelet count decreased, Thrombocytopenia, |
||||
RUXOLITINIB, BISOPROLOL FUMARATE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 821 | 24955970 |
US |
60 | 2 |
Pancytopenia, Gastroenteropancreatic neuroendocrine tumour disease, Malignant neoplasm progression, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 822 | 24956260 |
HU |
68 | 1 |
Prostate cancer metastatic, Malignant neoplasm progression, Osteonecrosis of jaw, |
||||
ZOLEDRONIC ACID, |
||||
| 823 | 24956298 |
MY |
||
Malignant neoplasm progression, Drug ineffective, |
||||
OLAPARIB, |
||||
| 824 | 24956371 |
CA |
59 | 2 |
Malignant neoplasm progression, |
||||
HUMAN IMMUNOGLOBULIN G, IBRUTINIB, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 825 | 24957167 |
JP |
41 | 2 |
Malignant neoplasm progression, Vomiting, Nausea, Pyrexia, Nausea, Pyrexia, Nausea, |
||||
ZOLBETUXIMAB, ZOLBETUXIMAB, ZOLBETUXIMAB, NIVOLUMAB, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, PALONOSETRON, PALONOSETRON HYDROCHLORIDE, PALONOSETRON, PALONOSETRON HYDROCHLORIDE, PALONOSETRON, PALONOSETRON HYDROCHLORIDE, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, CAPECITABINE, CAPECITABINE, CAPECITABINE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 826 | 24957189 |
JP |
7 | 1 |
Intestinal obstruction, Malignant neoplasm progression, |
||||
ZOLBETUXIMAB, ZOLBETUXIMAB, |
||||
| 827 | 24957362 |
CA |
73 | 1 |
Chronic myeloid leukaemia, Malignant neoplasm progression, Delirium, Pyrexia, Wound, |
||||
NILOTINIB, NILOTINIB, |
||||
| 828 | 24946596 |
JP |
||
Malignant neoplasm progression, |
||||
ENFORTUMAB VEDOTIN, |
||||
| 829 | 24946860 |
US |
66 | 2 |
Malignant neoplasm progression, |
||||
LENALIDOMIDE, LIDOCAINE PATCH 5%, BISACODYL, BISACODYL SUPPOSITORIES, BISCODYL, POLYETHYLENE GLYCOL 3350, ATOVAQUONE, FLUCONAZOLE, CALCIUM, PREDNISOLONE ACETATE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, VITAMIN E, CREAM, FOLIC ACID, BUPROPION HYDROCHLORIDE, BUPROPION, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, MAGNESIUM, |
||||
| 830 | 24946879 |
US |
68 | 1 |
Drug ineffective, Malignant neoplasm progression, COVID-19, Rhodococcus infection, Pancytopenia, Electrocardiogram QT prolonged, Product use in unapproved indication, |
||||
BENDAMUSTINE HCL, BENDAMUSTINE HCL, LENALIDOMIDE, LENALIDOMIDE, MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN, MINOCYCLINE, RITUXIMAB, RITUXIMAB, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, TAFASITAMAB-CXIX, TAFASITAMAB-CXIX, VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, RIFAMPIN, |
||||
| 831 | 24947728 |
CN |
74 | 1 |
Malignant neoplasm progression, Metastases to lung, Metastases to penis, Metastases to lymph nodes, |
||||
LEUPROLIDE ACETATE, BICALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, CELECOXIB, CELECOXIB, |
||||
| 832 | 24947827 |
CA |
70 | 1 |
Abdominal hernia, Malignant neoplasm progression, COVID-19, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
| 833 | 24948206 |
US |
88 | 2 |
Drug ineffective, Malignant neoplasm progression, Atrial fibrillation, Off label use, |
||||
LENALIDOMIDE, |
||||
| 834 | 24948365 |
GB |
2 | |
Malignant neoplasm progression, Neutropenia, Fatigue, |
||||
CARBOPLATIN, ABEMACICLIB, LETROZOLE, LETROZOLE TABLETS, |
||||
| 835 | 24948892 |
CA |
2 | |
Malignant neoplasm progression, Disease progression, Pneumonitis, |
||||
EVEROLIMUS, EVEROLIMUS TABLETS, |
||||
| 836 | 24950090 |
PL |
39 | 1 |
Follicular lymphoma, Malignant neoplasm progression, Metastases to bone, |
||||
RITUXIMAB, RITUXIMAB, LENALIDOMIDE, LENALIDOMIDE, |
||||
| 837 | 24950176 |
JP |
9 | 2 |
Malignant neoplasm progression, Product use issue, Off label use, |
||||
ZOLBETUXIMAB, FLUOROURACIL, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, OXALIPLATIN, |
||||
| 838 | 24950974 |
DE |
2 | |
Death, Hormone receptor positive HER2 negative breast cancer, Malignant neoplasm progression, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, ANASTROZOLE, ANASTROZOLE TABLETS, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, ALLOPURINOL, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, DAPAGLIFLOZIN, LISINOPRIL, MORPHINE, PREGABALIN, TIOTROPIUM BROMIDE, TORSEMIDE, TORSEMIDE, RIVAROXABAN, |
||||
| 839 | 24951432 |
CZ |
||
Anaemia, Neutropenia, Nausea, Decreased appetite, Fatigue, Malignant neoplasm progression, Vomiting, Diarrhoea, Arthralgia, Constipation, Abdominal pain, |
||||
OLAPARIB, |
||||
| 840 | 24952063 |
ES |
54 | 2 |
Skin toxicity, Hypothyroidism, Hepatitis, Rash maculo-papular, Rash, Palmar-plantar erythrodysaesthesia syndrome, Diarrhoea, Malignant neoplasm progression, |
||||
NIVOLUMAB, NIVOLUMAB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, |
||||
| 841 | 24952136 |
SK |
2 | |
Breast cancer, Malignant neoplasm progression, Osteomyelitis, Metastases to bone, Drug ineffective, |
||||
RIBOCICLIB, FULVESTRANT, |
||||
| 842 | 24952528 |
US |
||
Breast cancer metastatic, Malignant neoplasm progression, |
||||
LETROZOLE, LETROZOLE TABLETS, PALBOCICLIB, |
||||
| 843 | 24954797 |
72 | 1 | |
Malignant neoplasm progression, Prostatic specific antigen increased, Pain, Hypophagia, Weight decreased, Blood pressure decreased, Cardiac failure, Embolism, |
||||
APALUTAMIDE, |
||||
| 844 | 24944831 |
EC |
||
Malignant neoplasm progression, |
||||
TRASTUZUMAB, PERTUZUMAB, |
||||
| 845 | 24939907 |
CA |
71 | 2 |
Abdominal pain, Abdominal pain upper, Alopecia, Back pain, Eructation, Faeces discoloured, Fall, Fatigue, Flatulence, Frequent bowel movements, Injection site bruising, Injection site mass, Injection site pain, Loss of personal independence in daily activities, Malignant neoplasm progression, Musculoskeletal chest pain, Off label use, Pain in extremity, Pruritus, Pelvic fracture, Weight decreased, Flushing, Diarrhoea, Headache, Abdominal distension, Insomnia, Osteoporosis, Malaise, Therapeutic response shortened, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, LANREOTIDE ACETATE, LEMBOREXANT, DOXYLAMINE SUCCINATE, IVERMECTIN, MELATONIN, ERGOCALCIFEROL, |
||||
| 846 | 24940077 |
AT |
||
Breast cancer, Malignant neoplasm progression, PIK3CA-activated mutation, |
||||
BEVACIZUMAB, LETROZOLE, LETROZOLE TABLETS, PALBOCICLIB, CAPECITABINE, |
||||
| 847 | 24940274 |
JP |
8 | |
Malignant neoplasm progression, Nausea, Vomiting, |
||||
ZOLBETUXIMAB, |
||||
| 848 | 24940412 |
BR |
1 | |
Malignant neoplasm progression, Drug ineffective, |
||||
ABIRATERONE ACETATE, ABIRATERONE, |
||||
| 849 | 24940810 |
CA |
4 | |
Malignant neoplasm progression, Malignant glioma, |
||||
CISPLATIN, DABRAFENIB, TRAMETINIB, |
||||
| 850 | 24941922 |
IN |
3 | 1 |
Febrile neutropenia, Nausea, Vomiting, Drug intolerance, Malignant neoplasm progression, Drug ineffective for unapproved indication, |
||||
CAPECITABINE, DOCETAXEL, DOCETAXEL ANHYDROUS, CISPLATIN, |
||||
| 851 | 24942101 |
JP |
64 | 1 |
Encephalopathy, Neuropathy peripheral, Rectal abscess, Malignant neoplasm progression, |
||||
CETUXIMAB, FLUOROURACIL, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, OXALIPLATIN, METRONIDAZOLE, METRONIDAZOLE TOPICAL, |
||||
| 852 | 24942105 |
GB |
||
Deep vein thrombosis, Malignant neoplasm progression, Renal impairment, Therapy partial responder, |
||||
PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, |
||||
| 853 | 24942149 |
US |
1 | |
Prostate cancer metastatic, Metastases to bone, Malignant neoplasm progression, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 854 | 24942260 |
DE |
2 | |
Hormone receptor positive HER2 negative breast cancer, Malignant neoplasm progression, |
||||
EXEMESTANE, FULVESTRANT, RIBOCICLIB, RIBOCICLIB, |
||||
| 855 | 24942308 |
DE |
2 | |
Breast cancer metastatic, Malignant neoplasm progression, |
||||
FULVESTRANT, RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, |
||||
| 856 | 24943611 |
US |
66 | 2 |
Malignant neoplasm progression, |
||||
ABEMACICLIB, |
||||
| 857 | 24944047 |
US |
47 | 2 |
Hypokalaemia, General physical health deterioration, Blood creatinine increased, Gastrointestinal haemorrhage, Bacteraemia, Fungaemia, Metabolic acidosis, Malignant neoplasm progression, Drug ineffective, |
||||
LANREOTIDE ACETATE, LANREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE, CAPECITABINE, TEMOZOLOMIDE, |
||||
| 858 | 24933528 |
US |
56 | 1 |
Malignant neoplasm progression, Gastrointestinal disorder, Adverse event, |
||||
CABOZANTINIB, |
||||
| 859 | 24933530 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 860 | 24933532 |
US |
1 | |
Malignant neoplasm progression, Erythema, Limb discomfort, Rash vesicular, Oral pain, Fatigue, Decreased appetite, Dry skin, Dysgeusia, Drug effect less than expected, Stomatitis, Frequent bowel movements, Musculoskeletal pain, SARS-CoV-2 test positive, Scrotal exfoliation, Skin ulcer, Skin exfoliation, Arthralgia, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 861 | 24933536 |
AT |
41 | 2 |
Malignant neoplasm progression, Pyrexia, Vaginal haemorrhage, Oral pain, Cough, Diarrhoea, |
||||
CABOZANTINIB, CABOZANTINIB, APIXABAN, LENVATINIB, LENVATINIB, EVEROLIMUS, EVEROLIMUS TABLETS, |
||||
| 862 | 24933539 |
US |
2 | |
Pulmonary embolism, Malignant neoplasm progression, Off label use, |
||||
CABOZANTINIB, |
||||
| 863 | 24933542 |
AU |
71 | 1 |
Malignant neoplasm progression, Fatigue, Asthenia, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 864 | 24933543 |
US |
1 | |
Malignant neoplasm progression, Blood pressure increased, |
||||
CABOZANTINIB, |
||||
| 865 | 24933545 |
US |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 866 | 24933549 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 867 | 24933552 |
US |
1 | |
Pain, Malignant neoplasm progression, Hepatic enzyme increased, |
||||
CABOZANTINIB, CABOZANTINIB, AMLODIPINE, SULFAMETHOXAZOLE AND TRIMETHOPRIM, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PROCHLORPERAZINE MALEATE, ROPINIROLE, URSODIOL, URSOSIOL, SILDENAFIL CITRATE, |
||||
| 868 | 24933553 |
US |
2 | |
Malignant neoplasm progression, Drug ineffective, Fatigue, Dizziness, Walking aid user, Formication, Cough, Abdominal pain, |
||||
CABOZANTINIB, TIVOZANIB, |
||||
| 869 | 24933554 |
US |
1 | |
Malignant neoplasm progression, Thyroid hormones increased, Blood pressure increased, Fatigue, Diarrhoea, Feeling cold, |
||||
CABOZANTINIB, NIVOLUMAB, DOCUSATE SODIUM, DOCUSATE SODIUM - SENNOSIDES, IRON, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ERGOCALCIFEROL, |
||||
| 870 | 24933556 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 871 | 24933557 |
AT |
48 | 1 |
Malignant neoplasm progression, Nausea, Vomiting, |
||||
CABOZANTINIB, |
||||
| 872 | 24933559 |
US |
69 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 873 | 24933560 |
US |
2 | |
Malignant neoplasm progression, Gastrointestinal motility disorder, Mouth ulceration, Fatigue, Nausea, |
||||
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, |
||||
| 874 | 24933568 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 875 | 24933569 |
US |
1 | |
Malignant neoplasm progression, Drug ineffective, |
||||
CABOZANTINIB, |
||||
| 876 | 24933577 |
US |
||
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 877 | 24933578 |
US |
1 | |
Malignant neoplasm progression, Drug ineffective, |
||||
CABOZANTINIB, |
||||
| 878 | 24933581 |
PL |
||
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 879 | 24933584 |
US |
||
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 880 | 24933585 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 881 | 24933587 |
CO |
68 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 882 | 24933588 |
CO |
78 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 883 | 24933589 |
US |
2 | |
Malignant neoplasm progression, Off label use, |
||||
CABOZANTINIB, |
||||
| 884 | 24933590 |
CO |
55 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 885 | 24933591 |
PL |
55 | 2 |
Malignant neoplasm progression, Mucosal inflammation, Off label use, |
||||
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, NIVOLUMAB, LEVOTHYROXINE, NEBIVOLOL, NEBIVOLOL HYDROCHLORIDE, AMLODIPINE, LISINOPRIL, SPIRONOLACTONE, SPIRONOLACTONE, BISOPROLOL FUMARATE, BISOPROLOL FUMARATE, |
||||
| 886 | 24933596 |
AT |
1 | |
Malignant neoplasm progression, Off label use, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 887 | 24933597 |
US |
||
Malignant neoplasm progression, |
||||
CABOZANTINIB, ATEZOLIZUMAB, |
||||
| 888 | 24933603 |
MY |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 889 | 24933605 |
US |
2 | |
Malignant neoplasm progression, Adverse event, White blood cell count decreased, Off label use, |
||||
CABOZANTINIB, |
||||
| 890 | 24933606 |
US |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 891 | 24933608 |
CA |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, METOPROLOL TARTRATE, METOPROLOL, LORAZEPAM, AMLODIPINE, LEVOTHYROXINE SODIUM, |
||||
| 892 | 24933609 |
US |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 893 | 24933610 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 894 | 24933611 |
US |
1 | |
Malignant neoplasm progression, Metastases to spine, Metastases to lung, Blood iron decreased, Hypoacusis, Somnolence, Blood calcium decreased, Pain, Depression, Nausea, Decreased appetite, Constipation, Fatigue, Dyspnoea, Inappropriate schedule of product administration, |
||||
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, ATEZOLIZUMAB, DRONABINOL, AMLODIPINE BESYLATE, HYDRALAZINE HYDROCHLORIDE, EMPAGLIFLOZIN, LEVOTHYROXINE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, OXYCODONE HYDROCHLORIDE, OXYCODONE, CLOPIDOGREL, RAMIPRIL, ROSUVASTATIN, SPIRONOLACTONE, ERGOCALCIFEROL, |
||||
| 895 | 24933618 |
JP |
69 | 1 |
Malignant neoplasm progression, Drug intolerance, Fatigue, Weight decreased, Asthenia, Inappropriate schedule of product administration, |
||||
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, |
||||
| 896 | 24933624 |
US |
||
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 897 | 24933632 |
US |
1 | |
Malignant neoplasm progression, Drug ineffective, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 898 | 24933633 |
US |
73 | 1 |
Malignant neoplasm progression, Metastases to lung, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 899 | 24933637 |
US |
1 | |
Malignant neoplasm progression, Inappropriate schedule of product administration, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 900 | 24933639 |
MY |
71 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28